Literature DB >> 35058321

Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies.

Harm Westdorp1,2,3, Sarah R Verhoeff4,3, Martin Gotthardt4, Carla M L van Herpen3, Michel M van, den Heuvel5, Sandra Heskamp4, Erik H J G Aarntzen4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35058321      PMCID： PMC8978190          DOI： 10.2967/jnumed.121.262622

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  17 in total

1.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cell       Date:  2019-01-24       Impact factor: 41.582

2.  The Impact of FcγRI Binding on Immuno-PET.

Authors:  Delphine Vivier; Sai Kiran Sharma; Pierre Adumeau; Cindy Rodriguez; Kimberly Fung; Brian M Zeglis
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

Review 3.  De-novo and acquired resistance to immune checkpoint targeting.

Authors:  Nicholas L Syn; Michele W L Teng; Tony S K Mok; Ross A Soo
Journal:  Lancet Oncol       Date:  2017-12       Impact factor: 41.316

Review 4.  Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Robert Sidlow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

5.  89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.

Authors:  Frederike Bensch; Elly L van der Veen; Marjolijn N Lub-de Hooge; Annelies Jorritsma-Smit; Ronald Boellaard; Iris C Kok; Sjoukje F Oosting; Carolina P Schröder; T Jeroen N Hiltermann; Anthonie J van der Wekken; Harry J M Groen; Thomas C Kwee; Sjoerd G Elias; Jourik A Gietema; Sandra Sanabria Bohorquez; Alex de Crespigny; Simon-Peter Williams; Christoph Mancao; Adrienne H Brouwers; Bernard M Fine; Elisabeth G E de Vries
Journal:  Nat Med       Date:  2018-11-26       Impact factor: 53.440

Review 6.  Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.

Authors:  Xiaoli Ju; Heng Zhang; Zidi Zhou; Qiang Wang
Journal:  Am J Cancer Res       Date:  2020-01-01       Impact factor: 6.166

7.  Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake.

Authors:  Marlous Arjaans; Thijs H Oude Munnink; Sjoukje F Oosting; Anton G T Terwisscha van Scheltinga; Jourik A Gietema; Erik T Garbacik; Hetty Timmer-Bosscha; Marjolijn N Lub-de Hooge; Carolina P Schröder; Elisabeth G E de Vries
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

8.  Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.

Authors:  R de Vries; M Muller; V van der Noort; W S M E Theelen; R D Schouten; K Hummelink; S H Muller; M Wolf-Lansdorf; J W F Dagelet; K Monkhorst; A H Maitland-van der Zee; P Baas; P J Sterk; M M van den Heuvel
Journal:  Ann Oncol       Date:  2019-10-01       Impact factor: 32.976

9.  Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse.

Authors:  Frederike Bensch; Michaël M Smeenk; Suzanne C van Es; Johan R de Jong; Carolina P Schröder; Sjoukje F Oosting; Marjolijn N Lub-de Hooge; C Willemien Menke-van der Houven van Oordt; Adrienne H Brouwers; Ronald Boellaard; Elisabeth G E de Vries
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

10.  Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer.

Authors:  Anna-Larissa N Niemeijer; Daniela E Oprea-Lager; Marc C Huisman; Otto S Hoekstra; Ronald Boellaard; Berlinda J de Wit-van der Veen; Idris Bahce; Daniëlle J Vugts; Guus A M S van Dongen; Erik Thunnissen; Egbert F Smit; Adrianus J de Langen
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.